Literature DB >> 14504131

Rivastigmine blocks voltage-activated K+ currents in dissociated rat hippocampal neurons.

Yaping Pan1, Xianghua Xu, Xiaoliang Wang.   

Abstract

Rivastigmine is an acetylcholinesterase inhibitor used in Alzheimer's disease therapy. In the present study, we investigated the effects of rivastigmine on the transient outward K+ current (IK(A)) and the delayed rectifier K+ current (IK(DR)) in acutely dissociated rat hippocampal pyramidal neurons using the whole-cell patch-clamp technique. Rivastigmine inhibited the amplitudes of IK(A) and IK(DR) in a reversible and concentration-dependent manner. At a concentration of 100 mum, rivastigmine inhibited IK(A) and IK(DR), recorded when the cells were depolarized from -50 to +40 mV, by 65.9 (P<0.01) and 67.3% (P<0.01), respectively. The IC50 values for IK(A) and IK(DR) were 3.8 and 1.7 microM, respectively. The decay time constant of IK(A), recorded following a test pulse to +40 mV, was prolonged reversibly by rivastigmine at concentrations of 10 and 100 microM (both P<0.05). Rivastigmine affected the voltage dependence of IK(A) and IK(DR). At a concentration of 10 mum, it shifted the steady-state inactivation curve of IK(A) towards more negative potentials by -11 mV (P<0.05), but had no effect on the steady-state activation curve or the recovery from inactivation. Regarding the kinetic properties of IK(DR), 10 microM rivastigmine shifted the steady-state activation and inactivation curves towards more negative potentials by -10 (P<0.05) and -27 mV (P<0.01), respectively. Our findings that rivastigmine inhibits IK(A) and IK(DR) in rat hippocampal pyramidal neurons suggest that this agent has other pharmacological actions besides its antiacetylcholinesterase activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504131      PMCID: PMC1574096          DOI: 10.1038/sj.bjp.0705503

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status.

Authors: 
Journal:  Expert Opin Investig Drugs       Date:  1999-10       Impact factor: 6.206

Review 2.  Apoptosis in Alzheimer's disease--an update.

Authors:  S Shimohama
Journal:  Apoptosis       Date:  2000-02       Impact factor: 4.677

3.  Patch-clamp studies of voltage-gated currents in identified neurons of the rat cerebral cortex.

Authors:  O P Hamill; J R Huguenard; D A Prince
Journal:  Cereb Cortex       Date:  1991 Jan-Feb       Impact factor: 5.357

4.  Effects of tacrine, aminopyridines, and physostigmine on acetylcholinesterase, acetylcholine release, and potassium currents.

Authors:  A L Harvey; E G Rowan
Journal:  Adv Neurol       Date:  1990

5.  Mediation of neuronal apoptosis by enhancement of outward potassium current.

Authors:  S P Yu; C H Yeh; S L Sensi; B J Gwag; L M Canzoniero; Z S Farhangrazi; H S Ying; M Tian; L L Dugan; D W Choi
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

6.  Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons.

Authors:  M A Rogawski
Journal:  Eur J Pharmacol       Date:  1987-10-06       Impact factor: 4.432

7.  Selective blockade of the delayed rectifier potassium current by tacrine in Drosophila.

Authors:  D Kraliz; S Singh
Journal:  J Neurobiol       Date:  1997-01

8.  Huperzine A inhibits the sustained potassium current in rat dissociated hippocampal neurons.

Authors:  Yang Li; Guo-Yuan Hu
Journal:  Neurosci Lett       Date:  2002-08-30       Impact factor: 3.046

9.  Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons.

Authors:  Ya-Ping Pan; Xiang-Hua Xu; Xiao-Liang Wang
Journal:  Neurosci Lett       Date:  2003-01-09       Impact factor: 3.046

10.  Enhancement of outward potassium current may participate in beta-amyloid peptide-induced cortical neuronal death.

Authors:  S P Yu; Z S Farhangrazi; H S Ying; C H Yeh; D W Choi
Journal:  Neurobiol Dis       Date:  1998-08       Impact factor: 5.996

View more
  7 in total

Review 1.  Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels.

Authors:  Xian-Tao Li
Journal:  Metab Brain Dis       Date:  2022-01-31       Impact factor: 3.584

2.  QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine.

Authors:  Katie Malone; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

3.  The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers.

Authors:  R De La Garza; J J Mahoney; C Culbertson; S Shoptaw; T F Newton
Journal:  Pharmacol Biochem Behav       Date:  2008-01-22       Impact factor: 3.533

4.  Inhibitory effects of cholinesterase inhibitor donepezil on the Kv1.5 potassium channel.

Authors:  Kai Li; Neng Cheng; Xian-Tao Li
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

5.  MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy.

Authors:  Anas Shamsi; Saleha Anwar; Taj Mohammad; Mohamed F Alajmi; Afzal Hussain; Md Tabish Rehman; Gulam Mustafa Hasan; Asimul Islam; Md Imtaiyaz Hassan
Journal:  Biomolecules       Date:  2020-05-20

6.  Unraveling Binding Mechanism of Alzheimer's Drug Rivastigmine Tartrate with Human Transferrin: Molecular Docking and Multi-Spectroscopic Approach towards Neurodegenerative Diseases.

Authors:  Anas Shamsi; Taj Mohammad; Mohd Shahnawaz Khan; Moyad Shahwan; Fohad Mabood Husain; Md Tabish Rehman; Md Imtaiyaz Hassan; Faizan Ahmad; Asimul Islam
Journal:  Biomolecules       Date:  2019-09-17

Review 7.  Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.

Authors:  Yichang Huang; Mhd Wasem Alsabbagh
Journal:  Pharmacol Res Perspect       Date:  2020-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.